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Abstract
Background: Tuberculosis (TB) is a global public health problem, causing morbidity and mortality in adults and
children. The most reliable diagnostic tools currently available are the in vivo Tuberculin Skin Test (TST) and the
ex vivo Interferon-γ release assays (IGRAs). Several clinical, radiological, and bacteriological features make the
detection of active (overt disease) TB in children difficult. Although recently developed immunological assays such
as QuantiFERON-TB Gold In-Tube (QFT-IT) and T-SPOT®.TB are commonly used to identify active TB in adults,
different evidence is required for diagnosis in children. The purpose of this study was to reassess the sensitivity and
specificity of IGRAs in detecting microbiologically confirmed active TB in immunocompetent children.
Methods: A systematic review and meta-analysis of studies reporting on the diagnostic accuracy of tests for TB in
immunocompetent children aged 0–18 years, with confirmation by positive M. tuberculosis cultures, were undertaken.
Electronic databases were searched up to September 2015 and study quality assessment was performed using
QUADAS-2.
Results: Fifteen studies were included in our meta-analysis. Results showed that there were no significant differences
in sensitivity between TST (88.2 %, 95 % confidence interval [CI] 79.4–94.2 %), QFT-IT (89.6 %, 95 % CI 79.7–95.7 %) and
T SPOT (88.5 %, 95 % CI 80.4–94.1 %). However, both QFT-IT (95.4 %, 95 % CI 93.8–96.6 %) and T-SPOT (96.8 %, 95 % CI
94.2–98.5 %) have significantly higher specificity than TST (86.3 %, 95 % CI 83.9–88.6 %).
Conclusions: QFT-IT and T-SPOT have higher specificity than TST for detecting active TB cases in immunocompetent
children.
Keywords: Active tuberculosis, Children, Meta-analysis, Diagnosis, Tuberculin skin test, IGRAs, QuantiFERON-TB
Gold In-Tube, T-SPOT.TB
Background
Tuberculosis (TB) is one of the most important global
public health problems and one of the major causes of
adult and childhood morbidity and mortality worldwide.
In 2012, there were an estimated 530,000 TB cases (bac-
teriologically confirmed or clinically diagnosed) among
children <15 years of age, approximately 6 % of the total
number of 8.6 million cases. Among HIV-negative chil-
dren, there were 74,000 TB-related deaths, approximately
8 % of the total number of 940,000 TB-related deaths
among HIV-negative people [1].
In 2011, the trend in the pediatric TB notification rate
showed a slight decline during the previous ten years
from a peak of 5.7 in 2001. However, a number of coun-
tries, such as Bulgaria, Finland and Italy, have seen in-
creasing trends during the same period [2]. Indeed,
across Europe during the period 2000–2009, a decline or
stabilization of trends was reported in high-incidence
countries while low-incidence countries tended to report
an increased incidence in pediatric TB.* Correspondence: matteoraponi85@gmail.com
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In 2009, only 19.2 % of all childhood TB cases in Eur-
ope were confirmed by culture, a clear indication that
TB diagnosis in children remains a major public health
challenge [3]. Several clinical, radiological and bacterio-
logical features (such as pauci-bacillary nature, atypical
clinical signs, and a lower probability of bacteriological
confirmation) make the detection of active TB in chil-
dren difficult, often leading to the neglect of TB within
pediatric populations [4].
As a result, the diagnosis of active disease in children
often relies on a combination of contact history, clinical
symptoms, and radiological findings, together with a
consideration of the results of a Tuberculin Skin Test
(TST) [5, 6].
The most reliable diagnostic tools currently available
for identifying TB infection are the in vivo TST and the
ex vivo interferon-γ (IFN-γ) release assays (IGRAs). For
almost 100 years, the TST was the main test of choice
for identifying TB infection. This test measures an individ-
ual’s response to a solution of Mycobacterium tuberculosis
antigens and can produce false-positive and false-negative
responses due to immunologic immaturity or cross-
reactivity with mycobacteria not in the M. tuberculosis com-
plex, vaccination with Bacille Calmette-Guérin (BCG), and
other undetermined causes [7, 8]. Within the past decades,
however, two new immunological assays have been devel-
oped: the QuantiFERON-TB Gold (QFT-G; Qiagen),
QuantiFERON-TB Gold In-Tube (QFT-IT; Qiagen), and the
T-SPOT®.TB assay (Oxford Immunotec). QFT-G and QFT-
IT measure the concentration of IFN-γ produced in whole
blood by enzyme-linked immunosorbent assay (ELISA)
[8, 9]. T-SPOT measures the number of individual
Mycobacterium-specific T cells secreting IFN-γ by the
enzyme-linked immunosorbent spot (ELISPOT) assay
[10, 11].
In adults, a higher specificity of IGRAs compared with
TST has been reported. The sensitivity for active TB
ranges from 70 to 90 % and is lower in high TB inci-
dence settings [12–15]. Thus, IGRAs are now included
by the CDC in the recommended diagnostic algorithm
for detection of TB in adults [16]. However, caution is
recommended regarding their use in children [17].
A growing number of studies have compared TST and
IGRAs for the detection of M. tuberculosis infection, a
condition that may or may not progress to clinical dis-
ease and active (overt disease) TB in children. Studies
have measured sensitivity in populations with active TB
and in populations exposed to TB cases [18, 19]. Six
meta-analyses [6, 20–24] have previously assessed IGRAs’
sensitivity and specificity in children and reported largely
different pooled estimates. These differences are due to
the characteristics of the study populations and different
inclusion/exclusion criteria (such as immunologic status,
level of income, and concurrent infections). Two of these
previous meta-analyses focused on either bacteriologically
confirmed or clinically diagnosed TB cases [6, 22], one in-
cluded contacts with TB cases in addition to the previous
two categories [20], another also included cases of latent
TB [21] and one [23], although providing a sub-analysis
on microbiologically confirmed cases, included studies for
which it was not possible to clearly identify methods used
to confirm cases. In the last meta-analyses, which
provided a sub-analysis including only microbiologically
confirmed cases, the study population also included im-
munocompromised children [24]. Because of this hetero-
geneity, pooled estimates of sensitivity and specificity of
IGRAs and TST have varied considerably. Through the
use of different inclusion/exclusion criteria compared with
previous studies, the aim of our study was to reassess the
sensitivity and the specificity of IGRAs, QFT-IT, and
T-Spot TB versus TST in the detection of bacteriologic-




An extensive search of the scientific literature was car-
ried out by querying electronic databases of PubMed,
EMBASE and Cochrane Library to identify articles pub-
lished in English or Italian between January 1st 2003 and
September 30th 2015. The following terms were used as
keywords: “tuberculosis”, “tuberculosis infection”, or “tu-
berculosis disease”; “pediatrics” or “child*”; “Tuberculin
Test”; “Interferon-gamma Release Tests”, “Quanti-
FERON”, “ELISpot”, “QFT- IT”, “QFT-2G”, “IFN”, “T-
cell assays”, “T-SPOT.TB test”, “ESAT-6”, “CFP10”, or
“RD1 antigens”; “Sensitivity”; and “Specificity”. Further
retrieval of grey literature was conducted through con-
sulting Google Scholar and websites of the World Health
Organization (http://www.who.int/en/), Centre for Dis-
ease Control and Prevention (http://www.cdc.gov/) and
the National Institute for Health and Clinical Excellence
(https://www.nice.org.uk/) for relevant unpublished
studies and national and international guidelines. We in-
tegrated the electronic searches with manual searches,
checking the reference lists of relevant articles to identify
further studies.
Selection criteria
Potential studies were selected through consideration of
the title and abstract by two researchers. Disagreements
were solved by a senior researcher. Full texts of eligible
articles were read by two researchers to decide upon
final inclusion.
The following inclusion criteria were used: only studies
performed on healthy children from 0 to 18 years were
considered eligible, and articles which included only
adults or immunosuppressed children (such as HIV-
Laurenti et al. BMC Infectious Diseases  (2016) 16:131 Page 2 of 11
positive patients) were excluded; we included only those
studies focused on the sensitivity and specificity of
IGRAs or TST in detecting confirmed active TB cases
(considered as a child with active TB disease, confirmed
by positive M. Tuberculosis cultures); we included only
those studies including sensitivity and specificity, or
where it was possible to calculate them; we included
only articles that reported original data (reviews, case re-
ports and editorials were excluded); and we included
only those studies with ≥5 study subjects.
Quality assessment
Two independent researchers evaluated the validity of
the selected studies using the Revised Quality Assess-
ment of Diagnostic Accuracy Studies (QUADAS-2) tool
[25]. This tool assesses the risk for bias and concerns re-
garding applicability in four domains: patient selection,
index test, reference standard, and study flow and tim-
ing. The risk of bias was evaluated through the identifi-
cation of specific questions and the development of
guidance on items evaluation according to QUADAS-2
recommendations. The reviewers recorded and com-
pared the answers given to each question.
Both reviewers analysed all articles in terms of the
study population, index test, reference standard, setting,
diagnostic pathway, target condition, and flow diagram.
For each article, researchers independently recorded a
score of “low risk of bias/low concerns regarding applic-
ability,” “high risk of bias/high concerns,” or “unclear”
for each question. All domains with at least one negative
response scored “high risk of bias” (if the negative
response regarded the risk for bias) or “high concerns re-
garding applicability” (if the negative response regarded
the applicability), while domains with no negative re-
sponses but at least one unsure response scored “unclear”.
Domains with no negative and no unsure responses
scored “low risk of bias/low concerns”. All disagreements
were resolved by consensus.
Data abstraction and data analysis
Data were extracted using a standardized form including
the following information: authors, year of publication,
journal, country, country TB burden, study design, age
of the patients, sample size, TB diagnostic tests, and
TST cut-off. For each study, children representing true
positives (TP), true negatives (TN), false positives (FP),
and false negatives (FN) were defined by identifying
microbiological culture as the reference test. With re-
spect to TST, patients were classified as positive or nega-
tive according to the TST cut-off chosen by both the
authors of each paper and to all three TST cut-offs de-
fined by the American Academy of Paediatrics (AAP)
(>5 mm, >10 mm, >15 mm). The three cut offs sug-
gested by the AAP were applied to all patients of each
study because it was not possible to classify patients in
risk groups as defined by the AAP itself.
Two authors independently extracted data from the
papers and corroborated their findings. Pooled sensitivity
and specificity of TST, QFT-IT and T-SPOT and a 95 %
confidence interval (CI) were calculated using the Der
Simonian and Laird random effects model. Furthermore
summary receiving operating characteristic (sROC)
curves with Area Under the Curve (AUC) were obtained
on the basis of the Littenberg and Moses model. Meta-
Disc, version 1.4 (Hospital Ramony Cajal, Madrid, Spain)
[26] was used to perform the analysis. A value of 0.5 was
added to all cells in studies where any cell was 0. Hetero-
geneity was assessed using the I2 statistic. Pooled likelihood
positive and negative ratios (LR+ and LR-) were obtained
to assess the informative power of the three tests.
Results
Literature search
A total of 194 articles were obtained through database
searching. Among them, 169 articles were excluded after
abstract reading and a further 19 excluded after review
of the full text. Furthermore, after reviewing references
of retrieval articles, an additional nine studies were in-
cluded. A total of 15 studies [27–41] were included in
the systematic review (Fig. 1).
The included studies were undertaken in 11 countries,
of which four (Lithuania, China, India and Uganda)
[31, 33, 37, 39, 41] had a high TB burden. Among
studies considered in the analysis, six assessed both
the sensitivity and specificity of IGRAs and TST [27,
30, 31, 33, 36, 39]. The TST cut-off was set at 10 mm
in nine studies, 5 mm in four studies, 15 mm in one
study, and not defined in one. Regarding the IGRAs,
five assessed both QFT-IT and T-SPOT.TB, seven
only QFT-IT, and three only T-SPOT.TB. Characteris-
tics of all included studies are given in Table 1.
Quality assessment
Results of the quality assessment are summarized in
Table 2 and Fig. 2. Before disagreements were resolved,
reviewers’ consensus on risk for bias and concerns re-
garding applicability were 91.7 and 97.7 %, respectively.
No study was considered at low risk for bias in all the
domains while all studies scored low in terms of con-
cerns regarding applicability in all domains. The study of
Sun Lin et al. [33] and that of Cruz et al. [35] were con-
sidered to be the most at risk of bias; judged at high risk
in each domain with the exception of the Index Test do-
main (Sun Lin et al.) and Reference Standard domain
(Cruz et al.). The studies of Detjen et al. [27], Kampmann
et al. [29], Hansted et al. [31], and Chiappini et al. [36]
were considered to be less at risk for bias; judged at low
risk in each domain with the exception of the Patient
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Selection domain (Detjen et al. [27], Kampmann et al.
[29]) and Index Test domain (Hansted et al. [31] and
Chiappini et al. [23, 36]).
In the Patient Selection domain (domain 1), five studies
scored low risk for bias, one scored unclear risk (recruit-
ment protocol not clearly stated), and nine scored high risk
(sample of patients enrolled in a non-consecutive, non-
random way or inappropriate exclusions not avoided). In
the Index Test domain (domain 2), four studies had low
risk for bias, in seven cases it was unclear whether the
index test results were interpreted with or without know-
ledge of the results of the reference standard, and four
scored high risk (the index test results interpreted with
knowledge of the results of the reference standard). In the
Reference Standard domain (domain 3), seven studies
showed low risk for bias, six had unclear risk, and two
were judged at high risk for bias. Indeed, in six studies, it
was unclear if results of the reference standard were inter-
preted without knowledge of the index test, and in two
cases reviewers judged that results of the reference stand-
ard were interpreted with knowledge of the index test. In
the Flow and Timing domain (domain 4), seven studies
scored low risk for bias, while seven were judged at high
risk for bias, because not all patients recruited into the
study were included in the analysis, and one scored
unclear.
Diagnostic performance
TST (cut-off stated in the study), QFT-IT and T-SPOT
TP, TN, FP, and FN for each study are reported in
Table 3.
It was only possible to define TP, TN, FP and FN ac-
cording to the three TST cut off of AAP for two studies
(Detjen et al. [27], Chiappini et al. [23, 36]) (Table 4).
Pooled sensitivity and specificity
Accuracy of TST
Among six studies (Detjen et al. [27], Lighter et al. [30],
Hansted et al. [31], Sun Lin et al. [33], Chiappini et al.
[23, 36], Jenum et al. [39]), the overall sensitivity of the
TST (with respect to cut-off stated in each study) was
88.2 % (95 % CI 79.4–94.2 %). Of note, the degree of
Fig. 1 Flow chart of included studies
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Table 1 Characteristics of included studies
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Detjen et al.
(2007) [27]























Arch Dis Child. United Kingdom cross-sectional study 7.2 m-16 49 TST 0.82 – >15 Low
T-SPOT.TB 0.67 –
QFT-IT 0.78 –
Sun Lin et al.
(2010) [33]





































Table 1 Characteristics of included studies (Continued)
Chiappini et al.
(2014) [40]
Pediatr Infect Dis J. Italy cohort study <18 28210 TST 0.96a – – Low
QFT-IT 0.89a 0.96a
T-SPOT.TB 0.78a 0.99a
Petrone et al. (2015) [41] Biomed Res Int. Uganda cohort study 1 m - 16 7 TST 0.50a – ≥10 High
QFT-IT 0.60a –
a Sensitivity and specificity were not directly reported and were calculated from available data in the study












heterogeneity of the studies was high (I2 = 77.6 %)
(Fig. 3a). The pooled specificity was 86.3 % (95 % CI
83.9–88.6 %). Even here the degree of heterogeneity be-
tween the studies was high (I2 = 95.2 %) (Fig. 3b). Pooled
LR+ and LR- were 5.3 and 0.2, respectively and the AUC
was 0.925. Among the two studies (Detjen et al. [27],
Chiappini et al. [23, 36]) where calculation was possible,
the overall sensitivity of the TST, with respect to the AAP
cut-off of >5 mm, was 97.0 % (95 % CI 84.2–99.9 %) with
a heterogeneity of 74.7 %. The pooled specificity was
98.0 % (95 % CI 89.6–100 %) with a heterogeneity of
12.6 %. Using the AAP cut-off of >10 mm, the overall sen-
sitivity of the TST was 97.0 % (95 % CI 84.2–99.9 %) with
a heterogeneity of 74.7 %; the pooled specificity was 100 %
(95 % CI 93.0–100.0 %) with a heterogeneity of 0 %.
According to the AAP cut off > 15 mm, the overall sensi-
tivity of the TST was 60.6 % (95 % CI 42.1–77.1 %) with a
heterogeneity of 0 %; the pooled specificity was 100 %
(95 % CI 93.0–100.0 %) with a heterogeneity of 0 %.
Accuracy of the QFT-IT assay
Four studies (Detjen et al. [27], Lighter et al. [30], Chiap-
pini et al. [40], Jenum et al. [39]) included the QFT- IT
assay with a pooled sensitivity of 89.6 % (95 % CI 79.7–
95.7 %) (Fig. 3c). Heterogeneity between the studies was
absent (I2 = 0 %). The pooled specificity was 95.4 %
(95 % CI 93.8–96.6 %) (Fig. 3d) with slow heterogeneity
(I2 = 28.9 %). Pooled LR+ and LR- were 18.2 and 0.1, re-
spectively and AUC was 0.988.
Table 2 Results of the quality assessment according to the QUADAS-2 tool
Risk for bias Applicability concerns
Study Patient selection Index test Reference standard Flow and timing Patient selection Index test Reference standard
Detjen et al. (2007) [27] H L L L L L L
Domínguez et al. (2008) [28] U H L U L L L
Kampmann et al. (2009) [29] H L L L L L L
Lighter et al. (2009) [30] H U U L L L L
Hansted et al. (2009) [31] L H L L L L L
Bamford et al. (2010) [32] H L L H L L L
Sun Lin et al. (2010) [33] H L H H L L L
Tsolia et al. (2010) [34] L U H H L L L
Cruz et al. (2011) [35] H H L H L L L
Chiappini et al. (2012) [36] L H L L L L L
Lodha et al. (2013) [37] H U U L L L L
Blandinières et al. (2013) [38] H U U L L L L
Jenum et al. (2014) [39] L U U H L L L
Chiappini et al. (2014) [40] L U U H L L L
Petrone et al. (2015) [41] H U U H L L L
H high risk for bias, U unclear risk for bias, L low risk for bias
Fig. 2 Results of quality assessment according to the QUADAS-2 tool
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Accuracy of the T-spot assay
For determining sensitivity of the T-SPOT, four studies
(Detjen et al. [27], Hansted et al. [31], Sun Lin et al. [33],
Chiappini et al. [40]) were included in the analysis. It re-
sulted in a pooled sensitivity of 88.5 % (95 % CI 80.4–
94.1 %) (Fig. 3e). The degree of heterogeneity was
67.1 %. The pooled specificity was of 96.8 % (95 % CI
94.2–98.5 %) with a heterogeneity of 71.8 % (Fig. 3f ).
Pooled LR+ and LR- were 20.4 and 0.2 respectively and
the AUC was 0.978.
Discussion
Our study demonstrates that all the three tests were
highly accurate as shown by the AUC. According to the
confidence intervals of pooled estimates, there are no
significant differences in sensitivity among the three
methodologies assessed: TST pooled sensitivity: 88.2 %,
95 % CI 79.4–94.2 %; QFT-IT pooled sensitivity: 89.6 %,
95 % CI 79.7–95.7 %; and T-SPOT pooled sensitivity:
88.5 %, 95 % CI 80.4–94.1 %. However, with respect to
specificity, both QFT-IT (pooled specificity: 95.4 %, 95 %
CI 93.8–96.6 %) and T-SPOT (pooled specificity: 96.8 %,
95 % CI 94.2–98.5 %) performed significantly better than
TST (pooled specificity: 86.3 %, 95 % CI 83.9–88.6 %).
Subsequently, our findings highlight that IGRAs have a
higher specificity than TST for detecting active TB cases
in immunocompetent children.
For sensitivity, our results are consistent with the re-
cent findings of Sollai et al. [24] (TST pooled sensitivity:
79 %, 95 % CI 75–83 %; QFT-IT pooled sensitivity: 81 %,
95 % CI 76–85 %; T-SPOT pooled sensitivity: 80 %, 95 %
CI 74–84 %). Moreover, with respect to the previously
published meta-analysis, we have provided additional
evidence of a higher specificity of QFT-IT and T-SPOT
in bacteriologically confirmed active TB in immunocom-
petent children.
Since the sensitivity is equal, this improved specificity
of QFT-IT and T-SPOT ensures that healthy children
are not wrongly diagnosed as an active TB patient and
incorrectly treated as such, exposing them to two or
three drugs for at least six months. This improved speci-
ficity also reduces the negative emotional impact of a
false positive result on the families of children.
The diagnosis of active TB in children is especially
problematic as symptoms can be confused with those of
common childhood diseases and sputum samples are
Table 3 Results of TST, QFT-IT and T-SPOT.TB
Author, Year TST (cut-off stated in each study) QFT-IT T-SPOT.TB
TP TN FP FN TP TN FP FN IND TP TN FP FN IND
Detjen et al. (2007) [27] 28 22 0 0 26 21 0 2 1 26 21 0 2 1
Domínguez et al. (2008) [28] 9 – – 0 6 – – 3 0 6 – – 1 2
Kampmann et al. (2009) [29] 21 – – 3 20 – – 3 2 14 – – 9 1
Lighter et al. (2009) [30] 6 18 3 1 6 21 0 1 0 / / / / /
Hansted et al. (2009) [31] 23 18 34 0 / / / / / 23 47 5 0 0
Bamford et al. (2010) [32] 37 – – 8 36 – – 6 4 18 – – 8 1
Sun Lin et al. (2010) [33] 11 36 15 7 / / / / / 15 48 3 3 0
Tsolia et al. (2010) [34] 11 – – 2 11 – – 0 2 / / / / /
Cruz et al. (2011) [35] 10 – – 3 / / / / / 12 – – 1 0
Chiappini et al. (2012) [36] 4 28 1 1 0 29 0 5 0 / / / / /
Lodha et al. (2013) [37] 115 – – 13 102 – – 21 5 / / / / /
Blandinières et al. (2013) [38] 18 – – 5 16 – – 7 0 / / / / /
Jenum et al. (2014) [39] 3 624 65 1 3 625 33 1 20 / / / / /
Chiappini et al. (2014) [40] 27 – – 1 25 195 9 3 0 21 187 2 6 17
Petrone et al. (2015) [41] 3 – – 3 3 – – 2 0 / / / / /
TN true negatives, TP true positives, FN false negatives, FP false positives, IND indeterminate
Table 4 Results of TST (according to the three TST cut off of AAP)
Author, Year AAP cut off > 5 AAP cut off > 10 AAP cut off > 15
TP TN FP FN TP TN FP FN TP TN FP FN
Detjen et al. (2007) [27] 28 22 0 0 28 22 0 0 17 22 0 11
Chiappini et al. (2012) [36] 4 28 1 1 4 29 0 1 3 29 0 2
TN true negatives, TP true positives, FN false negatives, FP false positives
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harder to obtain. For these reasons, and because of the
higher specificity we have shown, the IGRAs could be
used as complementary tests to support the clinical diag-
nosis of active TB, in particular in the absence of bac-
teriological confirmation. However, it should always be
considered that a negative IGRA, as well as a negative
TST result, does not exclude active TB. This may be ap-
preciated by looking at LR+ and LR- which provide an
idea of the utility of the test. All the three tests we
assessed have similar LR- but different LR+ (5.3 for TST,
18.2 for QFT, and 20.4 for T-SPOT). This means that if
the ratio of the odds of having a negative test result in a
TB patient to the odds of the same result in a healthy
one is similar for the three tests, the ratio of the odds of
having a positive test result in a diseased patient to the
odds of the same result in a healthy child is much higher
using QFT and T-SPOT instead of TST. This makes
these tests useful in clinical practice as they allow clini-
cians to make a diagnosis of active TB [42].
The improved specificity in healthy children confirms
previous evidence [12, 43, 44], encouraging the primary
use of QFT-IT or T-SPOT for case finding among
healthy children and young patients [45]. These children
may also fail to present for TST reading as previously
suggested by Lewinsohn et al. [8]. From a Public Health
perspective, our results provide an opportunity to con-
sider the use of these tests in screening too. In fact, even
though all the tests we have assessed showed similar
sensitivities, IGRAs do not require, unlike TST, a second
visit to assess results, which may be problematic for
large and specific populations [46]. Furthermore, IGRAs
have been suggested to be more accurate than TST in
immunocompetent people [47] and allow distinguishing
individuals who have been previously vaccinated, which
could represent an advantage for screening. In fact,
IGRAs have already been used to screen children during
the investigation of potentially exposed newborns in a
Teaching Hospital [48] and the use of IGRAs in “one
step” approach has been also proposed in other contexts
[49, 50].
Limitations
Our study has a number of limitations. First, of all the
studies fulfilling our inclusion criteria considered small
populations. There is a small number of published stud-
ies focused on children, especially those aged <5 years.
In fact, caution should be exercised when considering
the preferential use of IGRAs in immunocompetent
Fig. 3 Plot of individual studies and pooled estimates of sensitivity and specificity. a sensitivity of TST, b specificity of TST, c sensitivity of QFT, d
specificity of QFT, e sensitivity of T-SPOT, f specificity of T-SPOT
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children aged <5 years; a warning to this effect was
added to the national guidelines in the United States in
a recent update [51]. Another limitation is the hetero-
geneity of studies, particularly concerning different and
specific age groups. We did not perform a sub-analysis
according to the size of TB burden (low versus high)
because of the small number of studies we were able to
include. For the same reason, a funnel plot was not used
to investigate potential publication bias. The indetermin-
ate rate results (inadequate interferon-γ response to
positive control (PHA/mitogen) due to anergy, excessive
interferon-γ in the negative control or, only for T-SPOT,
insufficient cells, < 250,000 cells/100 μl) among children,
which is considered an important impediment to the use
of IGRAs in clinical practice for children [51], was not
available in all the included studies. Further research
should focus on evaluating the additional value of safety,
social and ethical implications, organizational impact,
and cost-effectiveness of IGRAs on the basis of a Health
Technology Assessment approach.
Conclusions
QFT-IT and T-SPOT have a higher specificity than TST
for detecting active TB cases in immunocompetent chil-
dren, providing evidence for choices available to clinicians.
These tests may be used as complementary tests to sup-
port the clinical diagnosis of active TB and may be also
considered as part of public health responses.
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